Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy

Anemia is a key survival prognostic factor in lower-risk myelodysplastic syndromes (MDS). Lenalidomide (LEN) can correct anemia in 25% of MDS patients without deletion 5q (del5q). As this therapy will inevitably fail, understanding the outcome of these patients will facilitate development of subsequ...

Descripción completa

Detalles Bibliográficos
Autores principales: Prebet, Thomas, Toma, Andrea, Cluzeau, Thomas, Sekeres, Mikkael A., Vey, Norbert, Park, Sophie, Al Ali, Najla, Sugrue, Marie M., Komrokji, Rami, Fenaux, Pierre, Gore, Steven D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514957/
https://www.ncbi.nlm.nih.gov/pubmed/28184031
http://dx.doi.org/10.18632/oncotarget.15200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514957/
https://www.ncbi.nlm.nih.gov/pubmed/28184031
http://dx.doi.org/10.18632/oncotarget.15200

Ejemplares similares